Open AccessA Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
Author(s) -
David S. Hong,
Drew W. Rasco,
Michael H. Veeder,
Jason J. Luke,
Jason C. Chandler,
Ani Sarkis Balmanoukian,
Thomas J. George,
Pamela N. Münster,
Jordan Berlin,
Martin Gutierrez,
Alain C. Mita,
Heather A. Wakelee,
Selda Samakoglu,
Shanhong Guan,
Isaiah W. Dimery,
Thorsten Graef,
Erkut Borazanci
Publication year - 2019
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000500571
Subject(s) - ibrutinib , medicine , durvalumab , bruton's tyrosine kinase , pancreatic cancer , oncology , breast cancer , cancer , gastroenterology , tyrosine kinase , nivolumab , immunotherapy , leukemia , chronic lymphocytic leukemia , receptor
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase, is approved in the United States for the treatment of various B-cell malignancies. Preclinical data suggest synergistic antitumor activity of ibrutinib with programmed death-ligand 1 (PD-L1) inhibitors in solid tumors. This study evaluated ibrutinib plus durvalumab, a PD-L1-targeting antibody, in patients with relapsed/refractory solid tumors.